1887

Abstract

is a Gram-negative bacillus with intrinsic multidrug-resistant properties.

Herein, we present the first case report of human infection, relating to an implantable portal and catheter (port-a-cath) central line in a 5-year-old female with cystic fibrosis. The infection was identified using a Bruker MALDI-TOF Biotyper with BDAL (v12) of blood, which was cultured due to pyrexia and rigour following port-a-cath access. This report details the effective eradication of infection from the port-a-cath device using initial empirical gentamicin followed by targeted ciprofloxacin locks and systemic antibiotics.

We demonstrated successful eradication of from a port-a-cath device, including the minimum inhibitory concentrations (MICs) required in this case. The result was eradication of central access infection, preventing progression to bacteraemia/septicaemia and preserving central access in a child with cystic fibrosis and established respiratory disease.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000700.v3
2023-12-05
2024-02-25
Loading full text...

Full text loading...

/deliver/fulltext/acmi/5/12/acmi000700.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000700.v3&mimeType=html&fmt=ahah

References

  1. Izaguirre-Anariba DE, Sivapalan V. Chryseobacterium indologenes, an emerging bacteria: a case report and review of literature. Cureus 2020; 12:e6720 [View Article] [PubMed]
    [Google Scholar]
  2. Yang F, Liu H-M, Zhang R, Chen D-B, Wang X et al. Chryseobacterium shandongense sp. nov., isolated from soil. Int J Syst Evol Microbiol 2015; 65:1860–1865 [View Article] [PubMed]
    [Google Scholar]
  3. Nulens E, Bussels B, Bols A, Gordts B, Van Landuyt HW. Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device. Clin Microbiol Infect 2001; 7:391–393 [View Article] [PubMed]
    [Google Scholar]
  4. Lin Y-T, Jeng Y-Y, Lin M-L, Yu K-W, Wang F-D et al. Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia. J Microbiol Immunol Infect 2010; 43:498–505 [View Article] [PubMed]
    [Google Scholar]
  5. Esther CR, Plongla R, Kerr A, Lin F-C, Gilligan P. Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection. J Cyst Fibros 2016; 15:e45–e49 [View Article] [PubMed]
    [Google Scholar]
  6. Lambiase A, Del Pezzo M, Raia V, Sepe A, Ferri P et al. Chryseobacterium respiratory tract infections in patients with cystic fibrosis. J Infect 2007; 55:518–523 [View Article] [PubMed]
    [Google Scholar]
  7. Chen F-L, Wang G-C, Teng S-O, Ou T-Y, Yu F-L et al. Clinical and epidemiological features of Chryseobacterium indologenes infections: analysis of 215 cases. J Microbiol Immunol Infect 2013; 46:425–432 [View Article] [PubMed]
    [Google Scholar]
  8. Vay CA, Almuzara MN, Rodríguez CH, Pugliese ML, Lorenzo Barba F et al. “In vitro” activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp. Rev Argent Microbiol 2005; 37:34–45 [PubMed]
    [Google Scholar]
  9. Kirby JT, Sader HS, Walsh TR, Jones RN. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). J Clin Microbiol 2004; 42:445–448 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000700.v3
Loading
/content/journal/acmi/10.1099/acmi.0.000700.v3
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error